Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nevirapine plasma concentration is associated with virologic failure and the emergence of drug-resistant mutations among HIV patients in Kenya: A cross sectional study.

Medicine - 16 Dec 2022

Omondi Evans Okumu, Muigai Anne, Ngayo Musa Otieno, Mungiria Juster, Lihana Raphael

Abstract excerpt

This study aimed to determine the association between the plasma concentration of nevirapine (NVP) and clinical outcomes. In this cross-sectional study, sociodemographic and clinical data were collected from 233 HIV patients receiving NVP-based first-line antiretroviral therapy (ART) regimens in Nairobi, Kenya. The mean age was 41.2 (SD ± 11.9) years. Fifty-four (23.2%) patients had virological failure (>1000...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Cross-Sectional Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to HIV Infections

Share to Nevirapine

Share to Reverse Transcriptase Inhibitors

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 36550885
DOI: 10.1097/MD.0000000000032346
PMCID: PMC9771327

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nevirapine plasma concentration is associated with virologic failure and the emergence of drug-resistant mutations among HIV patients in Kenya: A cross sectional study.PMID 36550885Read ↗

Role of pharmacogenetics and clinical parameters on nevirapine plasma concertation among HIV-1 patients receiving Antiretroviral Therapy in KenyaSemantic proximity Read ↗

Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya: A cross-sectional study.Semantic proximity Read ↗

Prevalence of Pre-antiretroviral-Treatment Drug Resistance by Gender, Age, and Other Factors in HIV-Infected Individuals Initiating Therapy in Kenya, 2013-2014.Semantic proximity Read ↗

Nationwide patterns of HIV drug resistance and high viral load in Sub-Saharan African countries.Semantic proximity Read ↗

Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative surveySemantic proximity Read ↗

High Levels of Acquired HIV Drug Resistance Following Virological Nonsuppression in HIV-Infected Women from a High-Risk Cohort in Uganda.Semantic proximity Read ↗

Non-nucleoside reverse transcriptase inhibitors: a reviewSemantic proximity Read ↗

HIV viral non-suppression and drug resistance among persons who inject drugs on dolutegravir antiretroviral therapy in KenyaSemantic proximity Read ↗

The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study.Semantic proximity Read ↗

Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.Semantic proximity Read ↗

[Nevirapine as an important component of therapy for HIV infection].Semantic proximity Read ↗

Prevalence of human immunodeficiency virus-1 drug-resistant mutations among adults on first- and second-line antiretroviral therapy in a resource-limited health facility in Busia County, Kenya.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.